Search Results - "Herzog, J."

Brain Asymmetry Detection and Machine Learning Classification for Diagnosis of Early Dementia by Herzog, Nitsa J, Magoulas, George D

“…Early identification of degenerative processes in the human brain is considered essential for providing proper care and treatment. This may involve detecting…”
Get full text

Latest research and treatment of advanced-stage epithelial ovarian cancer by Coleman, Robert L., Monk, Bradley J., Sood, Anil K., Herzog, Thomas J.

“…Late-stage distribution and bulky intraperitioneal disease are the hallmarks of ovarian cancer presentation, which is managed primarily by surgical resection…”
Get full text

Lifetime of carbon capture and storage as a climate-change mitigation technology by Szulczewski, Michael L, MacMinn, Christopher W, Herzog, Howard J, Juanes, Ruben

“…In carbon capture and storage (CCS), CO2 is captured at power plants and then injected underground into reservoirs like deep saline aquifers for long-term…”
Get full text

Nationwide Trends in the Performance of Inpatient Hysterectomy in the United States by Wright, Jason D., Herzog, Thomas J., Tsui, Jennifer, Ananth, Cande V., Lewin, Sharyn N., Lu, Yu-Shiang, Neugut, Alfred I., Hershman, Dawn L.

“…To examine the use of inpatient hysterectomy and explore changes in the use of various routes of hysterectomy and patterns of referral. The Nationwide…”
Get full text

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer by Tewari, Krishnansu S, Burger, Robert A, Enserro, Danielle, Norquist, Barbara M, Swisher, Elizabeth M, Brady, Mark F, Bookman, Michael A, Fleming, Gini F, Huang, Helen, Homesley, Howard D, Fowler, Jeffrey M, Greer, Benjamin E, Boente, Matthew, Liang, Sharon X, Ye, Chenglin, Bais, Carlos, Randall, Leslie M, Chan, John K, Ferriss, J Stuart, Coleman, Robert L, Aghajanian, Carol, Herzog, Thomas J, DiSaia, Philip J, Copeland, Larry J, Mannel, Robert S, Birrer, Michael J, Monk, Bradley J

“…We report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly…”
Get full text

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer by Mirza, Mansoor R., Chase, Dana M., Slomovitz, Brian M., dePont Christensen, René, Novák, Zoltán, Black, Destin, Gilbert, Lucy, Sharma, Sudarshan, Valabrega, Giorgio, Landrum, Lisa M., Hanker, Lars C., Stuckey, Ashley, Boere, Ingrid, Gold, Michael A., Auranen, Annika, Pothuri, Bhavana, Cibula, David, McCourt, Carolyn, Raspagliesi, Francesco, Shahin, Mark S., Gill, Sarah E., Monk, Bradley J., Buscema, Joseph, Herzog, Thomas J., Copeland, Larry J., Tian, Min, He, Zangdong, Stevens, Shadi, Zografos, Eleftherios, Coleman, Robert L., Powell, Matthew A.

“…A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free…”
Get full text

Economic and energetic analysis of capturing CO2 from ambient air by House, Kurt Zenz, Baclig, Antonio C, Ranjan, Manya, van Nierop, Ernst A, Wilcox, Jennifer, Herzog, Howard J

“…Capturing carbon dioxide from the atmosphere ("air capture") in an industrial process has been proposed as an option for stabilizing global CO2 concentrations…”
Get full text

Residual Force Enhancement Following Eccentric Contractions: A New Mechanism Involving Titin by Herzog, W, Schappacher, G, DuVall, M, Leonard, T R, Herzog, J A

“…Eccentric muscle properties are not well characterized by the current paradigm of the molecular mechanism of contraction: the cross-bridge theory. Findings of…”
Get full text

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial by Coleman, Robert L, Prof, Brady, Mark F, Prof, Herzog, Thomas J, Prof, Sabbatini, Paul, Prof, Armstrong, Deborah K, Prof, Walker, Joan L, Prof, Kim, Byoung-Gie, Prof, Fujiwara, Keiichi, Prof, Tewari, Krishnansu S, Prof, O'Malley, David M, Prof, Davidson, Susan A, MD, Rubin, Stephen C, Prof, DiSilvestro, Paul, Prof, Basen-Engquist, Karen, Prof, Huang, Helen, MS, Chan, John K, MD, Spirtos, Nick M, MD, Ashfaq, Raheela, MD, Mannel, Robert S, MD

“…Summary Background Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial…”
Get full text

The impact of opportunistic salpingectomy on ovarian cancer mortality and healthcare costs: a call for universal insurance coverage by Naumann, R. Wendel, Hughes, Brittany N., Brown, Jubilee, Drury, Lane K., Herzog, Thomas J.

“…Opportunistic salpingectomy at the time of hysterectomy or as an alternative to bilateral tubal ligation may reduce the incidence of ovarian cancer, because it…”
Get full text

TDP-43 dysfunction restricts dendritic complexity by inhibiting CREB activation and altering gene expression by Herzog, Josiah J., Xu, Weijin, Deshpande, Mugdha, Rahman, Reazur, Suib, Hannah, Rodal, Avital A., Rosbash, Michael, Paradis, Suzanne

“…Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two related neurodegenerative diseases that present with similar TDP-43 pathology in…”
Get full text

The tidal disruption event AT 2018hyz – I. Double-peaked emission lines and a flat Balmer decrement by Short, P, Nicholl, M, Lawrence, A, Gomez, S, Arcavi, I, Wevers, T, Leloudas, G, Schulze, S, Anderson, J P, Berger, E, Blanchard, P K, Burke, J, Segura, N Castro, Charalampopoulos, P, Chornock, R, Galbany, L, Gromadzki, M, Herzog, L J, Hiramatsu, D, Horne, Keith, Hosseinzadeh, G, Howell, D Andrew, Ihanec, N, Inserra, C, Kankare, E, Maguire, K, McCully, C, Müller Bravo, T E, Onori, F, Sollerman, J, Young, D R

“…ABSTRACT We present results from spectroscopic observations of AT 2018hyz, a transient discovered by the All-Sky Automated Survey for Supernova survey at an…”
Get full text

Comparative Performance of the 2009 International Federation of Gynecology and Obstetricsʼ Staging System for Uterine Corpus Cancer by Lewin, Sharyn N., Herzog, Thomas J., Medel, Nicanor I. Barrena, Deutsch, Israel, Burke, William M., Sun, Xuming, Wright, Jason D.

“…OBJECTIVE:To perform a population-based analysis comparing the performance of the 1988 and 2009 International Federation of Gynecology and Obstetrics (FIGO)…”
Get full text

Theory-driven assessment of intentions and behaviours related to mobility of older inpatients: a survey of patients and healthcare professionals by Herzog, Philippe J, Herzog-Zibi, Rose D L, Möri, Charlotte, Mooser, Blandine, Aubert, Carole Elodie

“…Low mobility of patients during hospitalisation is associated with adverse outcomes. To successfully change behaviours related to mobility of older…”
Get full text

Comparative Effectiveness of Robotic Versus Laparoscopic Hysterectomy for Endometrial Cancer by WRIGHT, Jason D, BURKE, William M, WILDE, Elizabeth T, LEWIN, Sharyn N, CHARLES, Abigail S, KIM, Jin Hee, GOLDMAN, Noah, NEUGUT, Alfred I, HERZOG, Thomas J, HERSHMAN, Dawn L

“…Use of robotics in oncologic surgery is increasing; however, reports of safety and efficacy are from highly experienced surgeons and centers. We performed a…”
Get full text

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial by Monk, Bradley J, Prof, Poveda, Andrés, MD, Vergote, Ignace, MD, Raspagliesi, Francesco, MD, Fujiwara, Keiichi, MD, Bae, Duk-Soo, MD, Oaknin, Ana, MD, Ray-Coquard, Isabelle, MD, Provencher, Diane M, MD, Karlan, Beth Y, MD, Lhommé, Catherine, MD, Richardson, Gary, MD, Rincón, Dolores Gallardo, MD, Coleman, Robert L, MD, Herzog, Thomas J, MD, Marth, Christian, PhD, Brize, Arija, MD, Fabbro, Michel, MD, Redondo, Andrés, MD, Bamias, Aristotelis, PhD, Tassoudji, Marjan, MS, Navale, Lynn, MS, Warner, Douglas J, MD, Oza, Amit M, MD

“…Summary Background Angiogenesis is a valid target in the treatment of epithelial ovarian cancer. Trebananib inhibits the binding of angiopoietins 1 and 2 to…”
Get full text

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer by Monk, Bradley J, Herzog, Thomas J, Kaye, Stanley B, Krasner, Carolyn N, Vermorken, Jan B, Muggia, Franco M, Pujade-Lauraine, Eric, Lisyanskaya, Alla S, Makhson, Anatoly N, Rolski, Janusz, Gorbounova, Vera A, Ghatage, Prafull, Bidzinski, Mariusz, Shen, Keng, Ngan, Hextan Yuen-Sheung, Vergote, Ignace B, Nam, Joo-Hyun, Park, Youn Choi, Lebedinsky, Claudia A, Poveda, Andrés M

“…The objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women…”
Get full text

Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses by Coleman, Robert L., MD, Herzog, Thomas J., MD, Chan, Daniel W., PhD, Munroe, Donald G., PhD, Pappas, Todd C., PhD, Smith, Alan, MS, Zhang, Zhen, PhD, Wolf, Judith, MD

“…Background Women with adnexal mass suspected of ovarian malignancy are likely to benefit from consultation with a gynecologic oncologist, but imaging and…”
Get full text

Neuronal Activity of the Human Subthalamic Nucleus in the Parkinsonian and Nonparkinsonian State by Steigerwald, F, Potter, M, Herzog, J, Pinsker, M, Kopper, F, Mehdorn, H, Deuschl, G, Volkmann, J

“…1 Department of Neurology and 2 Department of Neurosurgery, Christian-Albrechts-Universität, Kiel, Germany Submitted 18 May 2008; accepted in final form 4…”
Get full text

Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients by Monk, Bradley J, Herzog, Thomas J, Tewari, Krishnansu S

“…Epithelial ovarian cancer (EOC) is responsible for more cancer-related deaths than any other malignancy of the female reproductive system. The standard of care…”
Get more information